These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 16385890)

  • 21. Detection of HIV drug resistance during antiretroviral treatment and clinical progression in a large European cohort study.
    Cozzi-Lepri A; Phillips AN; Clotet B; Mocroft A; Ruiz L; Kirk O; Lazzarin A; Wiercinska-Drapalo A; Karlsson A; Lundgren JD;
    AIDS; 2008 Oct; 22(16):2187-98. PubMed ID: 18832882
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Opinion paper. Resistance to new anti-HIV agents: problems in the pathway of drug registration.
    Dalmau D; Klimkait T; Telenti A
    Antivir Ther; 2005; 10(7):867-72. PubMed ID: 16312184
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HIV treatment decisions and transmitted drug resistance.
    Little SJ; Smith DM
    Clin Infect Dis; 2005 Jul; 41(2):233-5. PubMed ID: 15983921
    [No Abstract]   [Full Text] [Related]  

  • 24. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
    Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM
    AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A case of multidrug resistant primary HIV infection with delayed CD4 T-cell count decline despite low viral load, treated with interleukin-2.
    Pao D; Smit E; Imami N; Fisher M
    AIDS; 2006 Jul; 20(11):1564-5. PubMed ID: 16847417
    [No Abstract]   [Full Text] [Related]  

  • 26. Treatment interruptions in HIV-infected subjects.
    Bongiovanni M; Casana M; Tincati C; d'Arminio Monforte A
    J Antimicrob Chemother; 2006 Sep; 58(3):502-5. PubMed ID: 16816398
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Profile of drug-resistant case in New York.
    AIDS Patient Care STDS; 2005 May; 19(5):348. PubMed ID: 15945165
    [No Abstract]   [Full Text] [Related]  

  • 28. Ferrovir: a new antiviral drug for the treatment of HIV.
    Nossik D; Kaplina E; Nossik N; Sato S; Fomin Y; Voronin E
    Am Clin Lab; 2001; 20(9):36-8. PubMed ID: 11766418
    [No Abstract]   [Full Text] [Related]  

  • 29. Promoting HIV literacy.
    Zuniga JM
    J Int Assoc Physicians AIDS Care (Chic); 2008; 7(5):215-6. PubMed ID: 18987266
    [No Abstract]   [Full Text] [Related]  

  • 30. Managing antiretroviral therapy: changing regimens, resistance testing, and the risks from structured treatment interruptions.
    Eron JJ
    J Infect Dis; 2008 May; 197 Suppl 3():S261-71. PubMed ID: 18447612
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discordant immunological and virological responses to antiretroviral therapy.
    Schechter M; Tuboi SH
    J Antimicrob Chemother; 2006 Sep; 58(3):506-10. PubMed ID: 16854959
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Minority memory genomes can influence the evolution of HIV-1 quasispecies in vivo.
    Briones C; de Vicente A; Molina-París C; Domingo E
    Gene; 2006 Dec; 384():129-38. PubMed ID: 17059869
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HIV drug resistance and you. Resistance testing in experienced patients. Considerations when changing drugs.
    Posit Aware; 2006; Spec No():17-22. PubMed ID: 16596730
    [No Abstract]   [Full Text] [Related]  

  • 34. [Determination of serum levels of antiretroviral drugs].
    Kurowski M
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():62-4. PubMed ID: 15373053
    [No Abstract]   [Full Text] [Related]  

  • 35. Transmitted HIV-1 drug resistance: are we seeing just the tip of an epidemiological iceberg?
    Stekler J; Coombs RW
    J Infect Dis; 2007 Aug; 196(3):336-8. PubMed ID: 17597446
    [No Abstract]   [Full Text] [Related]  

  • 36. HIV-1 resistant strains acquired at the time of primary infection massively fuel the cellular reservoir and persist for lengthy periods of time.
    Ghosn J; Pellegrin I; Goujard C; Deveau C; Viard JP; Galimand J; Harzic M; Tamalet C; Meyer L; Rouzioux C; Chaix ML;
    AIDS; 2006 Jan; 20(2):159-70. PubMed ID: 16511408
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gender, ethnicity, and clinical trials.
    Jefferys R
    Women Alive; 2001; ():2-3, 16-7. PubMed ID: 11683006
    [No Abstract]   [Full Text] [Related]  

  • 38. Intermittent antiretroviral therapy in patients with controlled HIV infection.
    Marchou B; Tangre P; Charreau I; Izopet J; Girard PM; May T; Ragnaud JM; Aboulker JP; Molina JM;
    AIDS; 2007 Feb; 21(4):457-66. PubMed ID: 17301564
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drug resistance among chronic HIV-1-infected patients naïve for use of anti-retroviral therapy in Sao Paulo city.
    Gonsalez CR; Alcalde R; Nishiya A; Barreto CC; Silva FE; de Almeida A; Mendonça M; Ferreira F; Fernandes SS; Casseb J; Duarte AJ
    Virus Res; 2007 Nov; 129(2):87-90. PubMed ID: 17686543
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [HIV infection 2007].
    Potthoff A; Brockmeyer N;
    Med Klin (Munich); 2007 Jul; 102(7):531-9. PubMed ID: 17634871
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.